Zoladex LA 10.8 mg Injection

Zoladex LA 10.8 mg Injection

Prescription requiredRx Required

Salt Composition: Goserelin

Expiry Date: 01/2028

Special offer

Enquire

Inclusive of all taxes

▼

1 Injection

About The Product

Prostate Cancer

Zoladex 10.8mg Injection is an anticancer medicine with active ingredient Goserelin. It is prescribed to treat Prostate cancer in men. This medicine also given for Breast Cancer, Endometriosis, and Uterine Fibroids in women.

This medicine is a synthetic hormone that belongs to luteinizing hormone-releasing hormone (LHRH) agonists. It is used both in men and women but for different purposes. This injection should be administered under the skin by a doctor or experienced nurse. Don't self- administer it.

Overview

Zoladex LA 10.8 mg Injection contains goserelin acetate as its active ingredient and is classified under the category of drugs called GnRH agonists. This medication is used to treat hormone-related conditions like prostate cancer, breast cancer in women who have not yet undergone menopause, and endometriosis.

Zoladex LA 10.8 mg Injection mode of action is to lower the amounts of sex hormones that the body produces, such as testosterone in men and estrogen. The drug is available in the form of an implant that needs to be injected under the skin by a healthcare worker and is given every 12 weeks.

Common adverse effects of this Zoladex LA 10.8 mg Injection include hot flashes, sweating, headaches, mood swings, decreased libido, and reactions at the injection site. It should be taken only under medical supervision and in accordance with the instructions of the physician.

Quick Product Facts

Item

Detail

Active ingredient

Goserelin 10.8 mg (as acetate)

Form

Biodegradable implant in a single-dose SafeSystem syringe

Marketer

AstraZeneca Pharma India Ltd

Drug class

GnRH (LHRH) agonist

Route and frequency

Subcutaneous, anterior abdominal wall, every 12 weeks

Storage

Not above 30  °C  ; protect from moisture

Prescription status

Sold on the prescription of an oncologist only.

Price control

Appears in NPPA's revised-MRP lists for anti-cancer drugs

Price

Price of Zoladex LA 10.8 mg  may vary depending on the location, pharmacy and availability

Clinical Evidence for Zoladex LA 10.8 mg Injection

Zoladex 10.8 mg injection lowers testosterone as well as the 3.6 mg implant, and combined with radiotherapy it reduced local failure.

 

Study

Setting

Key result

Stage B2-C trial

466 men: Zoladex 3.6 mg + flutamide + radiotherapy vs radiotherapy alone

Local failure at 4 years 16% vs 33%. Distant spread 27% vs 36% (P = 0.058). Median disease-free survival 4.4 vs 2.6 years.

Two controlled trials

160 men with advanced prostate cancer: one 10.8 mg implant vs 3.6 mg implants every 4 weeks

Similar testosterone suppression. PSA fell 94% vs 92.5% at 3 months.

Four 10.8 mg implants

Testosterone over 336 days

Kept in the castrate range over the dosing interval in about 91% of men (145 of 160). One man never kept it there.

3.6 mg vs orchiectomy

Advanced prostate cancer

Long-term hormone and objective responses were similar. Survival was similar in a major trial.

Zoladex LA 10.8 mg Injection Side Effects

Most men notice the effects of low testosterone. The most common are hot flushes, sexual dysfunction, fewer erections and urinary symptoms. Zoladex 10.8 mg injection reduces sex drive, hot flushes, erectile dysfunction, and frequent sweating.

Effect

10.8 mg alone, weeks 12 to 48 (157 men)

Hot flushes

64%

Diarrhoea

not listed

Nausea

not listed

Skin rash

not listed

General pain

14%

Breast enlargement (gynaecomastia)

8%

Pelvic pain

6%

Bone pain

6%

Weakness (asthenia)

5%

Serious side effects

  • Tumor flare: testosterone rises briefly at the start. Bone pain can increase. Isolated cases of urinary blockage (ureteral obstruction) and spinal cord compression have occurred.

  • Allergy: antibody formation and acute anaphylactic reactions have been reported with GnRH agonists.

  • Blood sugar: high blood sugar and a higher risk of diabetes have been reported in men.

  • Heart and stroke: a small increase in heart attack, sudden cardiac death and stroke has been reported with GnRH agonists.

  • Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, and AGEP.

  • Heart rhythm: androgen deprivation may prolong the QT interval.

  • Injection-site injury: pain, bruising, bleeding, and, rarely, hemorrhagic shock needing transfusion or surgery. Extra care is needed in thin patients and those on full-dose anticoagulants.

  • Bones: lower bone density, osteoporosis, and fractures. Raised calcium can occur when cancer has spread to bone.

  • Pituitary: pituitary apoplexy, mostly within 2 weeks of the first dose, and pituitary tumors.

  • Mood and nerves: psychotic disorders, convulsions, and mood swings were reported after approval.

Critical Safety Warning

Call your local emergency number now for:

  • Sudden severe headache with vomiting, vision change, or confusion (possible pituitary apoplexy).

  • Chest pain, sudden weakness on one side, or slurred speech (possible heart attack or stroke).

  • Swelling of the lips, face, or throat; wheezing; or severe trouble breathing (anaphylaxis).

  • Soon after an injection: abdominal pain or swelling, breathlessness, dizziness, or fainting (possible bleeding from an injection-site injury).

  • Fever with a spreading rash, blisters, mouth or eye sores, or peeling skin (severe skin reaction).

Call your oncology team the same day for:

  • New or worsening bone pain, or trouble passing urine, in the first weeks (tumor flare).

  • New leg weakness or numbness, or loss of bladder control (possible spinal cord pressure).

  • Excessive thirst, or passing much more urine than usual (high blood sugar).

  • Palpitations, fainting, new leg swelling, or breathlessness.

  • Low mood, confusion, or unusual behavior.

  • Pain, a growing bruise or swelling at the injection site.

Zoladex LA 10.8 mg Injection Missed Dose

  • If you miss your scheduled Zoladex LA 10.8 mg injection, contact your healthcare provider as soon as possible to arrange a new appointment.
  • Every effort should be made to maintain the recommended 12-week dosing schedule.
  • Do not delay your next injection or change your treatment schedule without consulting your doctor.

Safety Advice for Zoladex LA 10.8 mg Injection

Alcohol
It is advisable not to consume alcohol while taking medicine.
Pregnancy
Do not take Zoladex 10.8mg injection without consulting the doctor, in case of pregnancy.
Breast Feeding
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
Do not take Zoladex 10.8mg injection without doctor's consultation in case of kidney problems.
Liver
Share your medical history with the doctor in case of liver disease before taking this medicine.

Monitoring During Zoladex LA Treatment

Check

Label guidance [1]

Why

Testosterone

Consider periodically if the expected response has not been reached; closely in obese men who have not responded

Confirm castrate levels

PSA

As your oncologist decides

PSA fell 94% at 3 months in the trial

Blood sugar and HbA1c

Periodically

Hyperglycaemia and diabetes

Heart symptoms

Watch for signs of heart disease

Heart attack, stroke

ECG and electrolytes

Consider periodically if QT risk

QT prolongation

Bones

Watch bone health; bisphosphonate may help

Bone loss, fractures

First month

Pain, urinary symptoms, nerve symptoms

Tumour flare

Skin

Monitor for severe skin reactions

Interrupt if suspected; stop if confirmed

Zoladex LA 10.8 mg Injection Fact Box

Item

Detail

Brand Name

Zoladex LA 10.8 mg Injection

Active ingredient

Goserelin 10.8 mg (as acetate)

Form

Biodegradable implant in a single-dose SafeSystem syringe

Marketer

AstraZeneca Pharma India Ltd

Drug class

GnRH (LHRH) agonist

Route and frequency

Subcutaneous, anterior abdominal wall, every 12 weeks

Storage

Not above 30°C ; protect from moisture

Chemical

Synthetic GnRH decapeptide analogue; goserelin molecular weight 1,269 Da

Implant

1.5 mm cylinder, total weight 36 mg, in a lactic and glycolic acid copolymer

Peak and trough levels (10.8 mg)

Peak about 8.85 ng/mL at about 1.8 hours; trough about 0.37 ng/mL

Protein binding

27%

Clearance

Mostly by hydrolysis; over 90% of a solution dose is excreted in urine

Pregnancy

May cause fetal harm and pregnancy loss

Zoladex LA 10.8 mg Injection Drug Interactions

Tell your team about every medicine you take, before starting Zoladex LA 10.8 mg Injection treatment.

 

Category

Interaction or Monitoring Details

Status

General drug interactions

No formal drug-interaction studies have been conducted, and no confirmed interactions have been reported. Inform your doctor about all medicines you take.

Precaution required

QT-prolonging medicines

Androgen deprivation may prolong the QT interval. Caution is advised with class IA and III antiarrhythmics, methadone, moxifloxacin, and antipsychotics.

Caution required

Blood thinners

No specific drug interaction is listed, but anticoagulants may increase the risk of injection-site bleeding.

Bleeding risk

Flutamide

Used in combination with Zoladex LA 10.8 mg Injection in certain prostate cancer treatment regimens involving radiotherapy (Stage B2–C).

Combined use

Laboratory tests

Hormone test results, including pituitary and sex-hormone tests, may be misleading during treatment.

Monitoring required

FAQs About Zoladex LA 10.8 mg Injection

Once every 12 weeks, which is 84 days. A doctor or nurse places one implant under the skin of the abdomen each time. The 3.6 mg implant is the one given every 28 days, so do not mix the two up. Keep to the schedule, although a delay of a few days is permissible.

References

  1. TerSera Therapeutics. ZOLADEX (goserelin implant) 10.8 mg, US prescribing information, revised 09/2025.

  2. NPPA. Revised MRP of non-scheduled anti-cancer drugs, lists of 28 October and 5 November 2026.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Magicine PharmacopyCopyright 2026